AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02593058 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
Study NCT00587769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion SR & Varenicline
Description: Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.~Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
Study NCT01728142 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DANA Brief
Description: The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
Study NCT01728142 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DANA Brief
Description: The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
Study NCT01728142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ANAM
Description: The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
Study NCT01728142 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ANAM
Description: The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
Study NCT02102243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEFINITY® infusion
Description: The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
Study NCT03334474 — intervention group
Intervention type: OTHER
Description: no intervention
Study NCT02102243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Recombinant Regular Insulin infusion
Description: The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
Study NCT02102243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose infusion
Description: The plasma glucose concentration will be held constant at 90 mg/dl by a variable glucose infusion during euglycemic hyperinsulinemic clamp
Study NCT02102243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flow mediated vasodilation
Description: Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
Study NCT02102243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endothelial cell collection
Description: We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
Study NCT02102243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microvascular perfusion assessment using Definity
Description: Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
Study NCT02102243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneurography
Description: Sympathetic nerve activity from the peroneal nerve measured by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. .The recording needle will remain in position throughout the study.
Study NCT02055950 — intervention group
Intervention type: PROCEDURE
Intervention: Storage of kidney in refrigerated solution
Study NCT02055950 — intervention group
Intervention type: PROCEDURE
Intervention: Kidney perfused by pulsatile machine
Study NCT01626573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Study NCT01626573 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itacitinib Placebo
Study NCT02025998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibudilast
Description: Ibudilast is a glial cell modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor.
Study NCT01754207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite Laser
Study NCT01754207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser with CAP Array
Description: 755nm Alexandrite Laser with CAP Array
Study NCT04101435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S (QIS)
Description: This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.
Study NCT04101435 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AdimFlu-S (QIS)
Description: This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.
Study NCT01310218 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: extended postoperative dressing
Description: 2 weeks of bulky dressing
Study NCT01310218 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: short postoperative dressing
Description: 2 days bulky dressing followed by bandaid
Study NCT02447458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets
Study NCT02447458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MLN3126 Placebo
Description: MLN3126 placebo-matching tablets
Study NCT03219892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Description: It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.
Study NCT03219892 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.
Study NCT00643357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)
Description: gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
Study NCT00643357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 50%Oxygen/50% Nitrogen premix
Description: inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
Study NCT04082702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith-enhanced diabetes prevention program
Description: The faith-enhanced curriculum was faith-based and developed using CBPR approaches. The Faith-DPP condition included delivery of the DPP. The group intervention was delivered by one to two trained peers from the church and consisted of 16 weekly group meetings followed by 6 bi-monthly or monthly maintenance sessions. The faith enhanced curriculum included five strategies: 1) a mini sermon (\~15 min in length) delivered by a pastor (head pastors were required to deliver at least one per month), first lady, or church leader (pastor associate, deacon, elder, etc.), 2) a memory verse, 3) in class or take-home faith activity (application of faith principles), 4) promises to remember, and 5) scripture and prayer integrated into participant curriculum and facilitator materials. These five faith enhancements were developed by the CAB to enhance the DPP's weekly learning objectives, which resulted in faith components specifically linked to each week of DPP content.
Study NCT04082702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard diabetes prevention program
Description: The S-DPP condition was faith-placed, a secular program (the DPP) held at an faith-based organization. This condition received the same diabetes prevention program (DPP) as the Faith-DPP, but did not receive any faith enhancements or pastor involvement.
Study NCT03061045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]
Description: All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
Study NCT00546429 — intervention group
Intervention type: DEVICE
Intervention: Intramedullary nailing
Description: Trochanteric nailing for proximal femoral fractures.
Study NCT02679495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active measures of lifestyle modification
Study NCT01089829 — intervention group
Intervention type: OTHER
Intervention: Foot examination
Description: Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system
Study NCT01923233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: allogeneic Th1 memory cell with CD3/CD28-coated microbeads attached.
Study NCT02496117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical mapping, nerve stimulation checked renal denervation procedure
Study NCT02496117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrial mapping, nerve stimulation guided renal denervation procedure
Study NCT01138865 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AutoSet Spirit--Wash--Modified-AutoSet Spirit
Description: 3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
Study NCT01138865 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Modified-AutoSet Spirit--Wash-AutoSet Spirit
Description: 3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
Study NCT02590835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic procedures (for both groups : Control group and Test group)
Description: Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
Study NCT02590835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic procedures (for both groups : Control group and Test group)
Description: Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
Study NCT02590835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezo-assisted orthodontics (only the Test group)
Description: The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
Study NCT03962582 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matrix back
Description: The Matrix back will replace the individual's back and the measures will be taken.
Study NCT03075319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Received perioperative photograph
Description: All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups.
Study NCT02025998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: A matched placebo (suggar pill) will be administered as a control condition.
Study NCT03075319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Didn't receive perioperative photograph
Description: All participants in active comparator group didn't receive perioperative knee photograph.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups.
Study NCT00929331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: Intramuscular injection, one dose
Study NCT01213693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone combination
Description: Salmeterol/Fluticasone 50/500 mcg 1 inhalation bid
Study NCT02127775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (manufactured at Site 1)
Study NCT02127775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (manufactured at Site 2)
Study NCT01206816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727 + BIBW 2992
Description: BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
Study NCT00973765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bactrim
Description: bactrim DS (800/160) 2 pills PO BID x 7 days
Study NCT00973765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 2 pills po BID x 7 days
Study NCT04243408 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood transfusion
Description: single dose of an autologous umbilical cord blood transfusion
Study NCT04243408 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml
Study NCT02115217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leukotape K
Description: All interventions will be performed by a qualified physiotherapist in a standardized manner. Tape will be extended to the recommended length (120%) and applied along the outer side of the leg, along the path of the peroneal muscle. Starting in the middle of the foot arch, the tape ends 1 cm below tibial head.
Study NCT02115217 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham kinesiotape
Description: KT put with no effects
Study NCT00229736 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV-hAADC-2
Description: 9 x 10\^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
Study NCT00229736 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV-hAADC-2
Description: 3 x 10\^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
Study NCT04872972 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Simulation based learning
Description: Faculty development courses on simulation based learning
Study NCT02823483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Lotion (BAY987521)
Description: 50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.Formulation A: Y49-103, Formulation B: Y71-150.
Study NCT02823483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated Skin
Description: This site is patched without treatment as irradiated control
Study NCT02890836 — intervention group
Intervention type: DRUG
Intervention: Antihypertensiva, mainly Metyldopa
Study NCT03537274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-Intron
Description: PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.
Study NCT03537274 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Alfa-2B
Description: Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.
Study NCT04430855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral
Study NCT04430855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet; Oral
Study NCT01213693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol 50 mcg 1 inhalation bid
Study NCT02602717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lymph nodes cyto-punction
Study NCT00430495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
Study NCT00430495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
Study NCT00430495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
Study NCT00430495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to atacicept
Description: Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.